Don’t get confused with all the various prostate cancer terms and drugs. The following resources can help you with these. You can also find these links in the Resources section of this website.
Men who are initially diagnosed with intermediate-risk prostate cancer may or may not be good candidates for Active Surveillance. This excellent article begins to provide a basis for making that determination. You can read the article by clicking HERE.
So you’ve had your PSA test, and it came back high. Your doctor did a DRE and ran a few more tests, and assures you that prostate cancer is very unlikely. Still, you’re worried. What are some other causes of a high PSA?
Read about this in the Prostate Care Foundation blog HERE
Prostate Cancer International announces the development and official opening of its online Active Surveillance Virtual Support Group. This group will meet by webinar or conference call once a month, with the next webinar on Wednesday, December 6, at 2:00 pm Eastern Time (11:00 am Pacific). Registration is required to join.
For more information, click here
Dr. Mark Scholz participated in a tumor board session with a discussion of Prostate Cancer Cases at El Camino Hospital in November 2017.
- Robert Sinha, MD, Medical Director of Radiation Oncology
- Frank Lai, MD, Urological Oncologist/Robotic Surgeon, El Camino Hospital
- Steven Kurtzman, MD, Radiation Oncologist, Director of Prostate Brachytherapy, El Camino Hospital
- Shane Dormady, MD PhD, Medical Director of Oncology, El Camino Hospital
- Mark Scholz, MD, Medical Oncology, Director of Prostate Cancer Specialists, Founder of Prostate Cancer Research Institute
View the recording of the event here
The Prostate Cancer Patient Guide, available from pcf.org is a useful and a must-have resource for prostate cancer patients, loved ones, or caregivers.
Download it from the pcf.org web site here
A Short Course in Prostate Cancer – eBook
The purpose of this short eBook is to provide men facing prostate cancer with a lot of up-to-date information in a compact format.
The information and opinions provided in this book are not specific medical advice for any individual. It should not substitute for medical advice from a healthcare professional. The author is not a medical doctor. The reader is advised that any information or opinions expressed or implied in this book are those of a layman and should not be acted upon without the consent of a licensed physician. This book is not meant to be used, nor should it be used, to diagnose or treat any medical condition. For diagnosis or treatment of any medical problem, consult your own physician.
Download the pdf ebook here.
Risk Assessment systems are not intended to replace individualized clinician-patient decision making, but rather to provide a straightforward instrument for facilitating disease risk classification in clinical decision making and in future research.
The classification developed by D’Amico and colleagues is one of the most widely used and is a good starting point for risk assessment. This system uses PSA level (blood test), Gleason grade (microscopic appearance of the cancer cells), and T stage (size of the tumor on rectal exam and/or ultrasound) to group men as low, intermediate, or high-risk.
Low-risk: PSA less than or equal to 10, Gleason score less than or equal to 6, and clinical stage T1-2a
Intermediate risk: PSA between 10 and 20, Gleason score 7, or clinical stage T2b
High-risk: PSA more than 20, Gleason score equal or larger than 8, or clinical stage T2c-3a
Limitations: Does not account for multiple risk factors
Read more and access the risk assessment calculator here on the UCSF site
According to an article in the journal Cancer, men with low-risk prostate cancer diagnosed and managed at high-volume hospitals are 3.6 times more likely to be managed on active surveillance than those managed at low-volume institutions.
Read more here on Prostate Cancer InfoLink
Watch video on www.urotoday.com